Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

Documenti analoghi

• Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
  di: Devonshire, Virginia, et al.
  Pubblicazione: (2010)
• Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study
  di: Singer, Barry, et al.
  Pubblicazione: (2012)
• Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
  di: Dwyer, Michael G., et al.
  Pubblicazione: (2015)
• Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
  di: Ahmed, Hamdy MA, et al.
  Pubblicazione: (2018)
• Multiple Subcutaneous Cysts in the Arms
  di: Cautley, Edmund
  Pubblicazione: (1914)